Hiratsuka, Japan

Mitsugi Shibano

This inventor holds 2 USPTO granted patents. Top assignee: Sankyo Company, Limited. Active years: 1995-1997.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 1995-1997

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Mitsugi Shibano: Innovator in Milbemycin Derivatives

Introduction

Mitsugi Shibano is a notable inventor based in Hiratsuka, Japan. He has made significant contributions to the field of chemistry, particularly in the production of milbemycin derivatives. With a total of 2 patents, his work has implications in various applications.

Latest Patents

Shibano's latest patents focus on processes for the production of 13-ether derivatives of milbemycins. One of his patents details an intermediate useful in the synthesis of milbemycin derivatives that feature an ether bond at the 13-position. This intermediate is represented by a specific general formula, wherein R can be a methyl, ethyl, isopropyl, or sec-butyl group. Additionally, R5 and R6 each represent either a hydrogen atom or a protecting group. These innovations are crucial for advancing the synthesis of milbemycin derivatives and their related precursors.

Career Highlights

Mitsugi Shibano is associated with Sankyo Company, Limited, where he has been able to apply his expertise in the development of pharmaceutical compounds. His work has contributed to the company's reputation in the industry.

Collaborations

Shibano has collaborated with notable coworkers such as Shunshi Kojima and Mutsauo Suzuki. Their combined efforts have furthered research and development in their field.

Conclusion

Mitsugi Shibano's contributions to the field of milbemycin derivatives highlight his innovative spirit and dedication to advancing chemical processes. His patents reflect a commitment to enhancing pharmaceutical development, making him a significant figure in his industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…